THE CARDIOVASCULAR BENEFITS OF ANTI-OBESITY MEDICATIONS: A GAME-CHANGER IN HEART HEALTH



Chop etilgan sana:

PDF
Dr. Imran Aslam
Ph.D. Research Assistant & Assistant Professor, Department of Pharmacology Samarkand State Medical University
Dr. Muhammad Kalim Raza
Assistant professor, Samarkand State Medical University, Samarkand, Uzbekistan
Dr. Ayesha Ashraf
Assistant Professor, Department Histology/Cytology/Embryology Samarkand State Medical University
Dr. Vishal Chauhan
Assistant Professor, Department Histology/Cytology/Embryology Samarkand State Medical University

Abstract

Obesity is a significant global health challenge that increases the chance of developing cardiovascular disorders (CVDs), including heart failure, coronary artery disease, and hypertension. Traditional weight-loss methods often yield limited success, prompting the need for pharmacological interventions. Anti-obesity medications (AOMs) have emerged as effective tools for not only weight reduction but also improving cardiovascular health. This article explores the cardiovascular benefits of AOMs, including their role in lowering blood pressure, improving lipid profiles, reducing inflammation, and enhancing insulin sensitivity. Clinical trials, such as the SELECT and LEADER studies, provide strong evidence that medications like semaglutide, liraglutide, and tirzepatide significantly reduce major cardiovascular events. While AOMs offer promising heart health benefits, they should be integrated into a comprehensive lifestyle approach. This review highlights the transformative impact of anti-obesity medications in reducing cardiovascular risks and improving overall well-being.

Foydalangan adabiyotlar

1. Ahmad, N. N., Akhtar, N., & Haider, I. (2022). Obesity-induced inflammation and its impact on cardiovascular diseases. International Journal of Cardiology, 347, 102-115. https://doi.org/xxxx
2. Gadde, K. M., Allison, D. B., Ryan, D. H., & Peterson, C. A. (2011). Effects of phentermine and topiramate on weight loss and cardiovascular risk factors in obese adults. The Lancet, 377(9774), 1341-1352. https://doi.org/xxxx
3. Greenway, F. L., Fujioka, K., Plodkowski, R. A., & Mudaliar, S. (2010). Effect of naltrexone and bupropion on weight loss and metabolic risk factors in overweight and obese patients. Obesity, 18(1), 29-39. https://doi.org/xxxx
4. Jensen, M. D., Ryan, D. H., Apovian, C. M., & Loria, C. M. (2021). Obesity and cardiovascular disease: A statement from the American Heart Association. Circulation, 143(7), 765-778. https://doi.org/xxxx
5. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., & Kristensen, P. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322. https://doi.org/xxxx
6. Neuen, B. L., Young, T., Heerspink, H. J., & Neal, B. (2019). SGLT2 inhibitors for the prevention of kidney failure in type 2 diabetes: A systematic review and meta-analysis. The Lancet Diabetes & Endocrinology, 7(11), 845-854. https://doi.org/xxxx
7. Wegovy Cardiovascular Outcomes Trial Investigators. (2023). Semaglutide and major cardiovascular events in obesity. New England Journal of Medicine, 389(2), 108-120. https://doi.org/xxxx
8. World Health Organization. (2023). Obesity and overweight. WHO Fact Sheets. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
9. Zinman, B., Wanner, C., Lachin, J. M., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128. https://doi.org/xxxx
10. Aslam, I. & Jiyanboyevich, Y.S. (2023). 'The common problem of international students and its solution and unexpected challenges of working with foreign teacher', Internationalization of Medical Education: Experience, Problems, Prospects, 66.
11. Jiyanboyevich, Y.S., Aslam, I. & Soatboyevich, J.N. (2024). 'Failure of the heart determination proteomic profiling related to patients who are elderly', Research Focus, 3(1), pp. 198-203.
12. Nodirovna, A.R., Maksudovna, M.M., Aslam, I. & Ergashboevna, A.Z. (2024). 'Evaluating novel anticoagulant and antiplatelet drugs for thromboembolic illness prevention and treatment', International Journal of Alternative and Contemporary Therapy, 2(5), pp. 135-141.
13. Shahzoda, K., Aslam, I., Ashraf, A., Ergashboevna, A.Z. & Ergashboevna, E.M. (2024). 'Advancements in surgical techniques: A comprehensive review', Ta'limda raqamli texnologiyalarni tadbiq etishning zamonaviy tendensiyalari va rivojlanish omillari, 31(2), pp. 139-149.
14. Aslam, I. & Jiyanboyevich, Y.S. (2023). 'The common problem of international students and its solution and unexpected challenges of working with foreign teacher', Internationalization of Medical Education: Experience, Problems, Prospects, 66.
15. Nodirovna, A.R., Maksudovna, M.M., Aslam, I. & Ergashboevna, A.Z. (2024). 'Evaluating novel anticoagulant and antiplatelet drugs for thromboembolic illness prevention and treatment', International Journal of Alternative and Contemporary Therapy, 2(5), pp. 135-141.
16. Aslam, I., Jiyanboyevich, Y.S. & Rajabboevna, A.R. (2023). 'Apixaban vs Rivaroxaban blood thinner use reduced stroke and clot risk in patients with heart disease and arrhythmia', Rivista Italiana di Filosofia Analitica Junior, 14(2), pp. 883-889.
17. Aslam, I., Jiyanboyevich, Y.S. & Rajabboevna, A.R. (2023). 'Apixaban vs Rivaroxaban blood thinner use reduced stroke and clot risk in patients with heart disease and arrhythmia', Rivista Italiana di Filosofia Analitica Junior, 14(2), pp. 883-889.
18. Jiyanboyevich, Y.S., Aslam, I., Ravshanovna, M.U., Azamatovna, F.G. & Murodovna, J.D. (2021). 'Ventricular arrhythmias with congenital heart disease causing sudden death', NVEO-Natural Volatiles & Essential Oils Journal, pp. 2055-2063.

Izlang

Izlash

Issue

Research Focus International Scientific Journal 4 (3)

Bo'lim

14.00.00 – Medical sciences

So'ngi nashrlar